Palopegteriparatide

Palopegteriparatide (brand name Yorvipath) is a synthetic hormone replacement therapy used for treating hypoparathyroidism in adults. It is a transiently pegylated analog of parathyroid hormone (PTH), designed as a prodrug that releases PTH(1-34) in a controlled manner to maintain calcium homeostasis. It is grouped under the following drug class(es): Hormones and Peptides. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Yorvipath and ACP-014. Its PubChem SID is 505854365.

CAS No 2222514-07-8
Molecular Formula C₂₀₉H₃₄₀N₆₀O₅₉S₃ + 2 × (C₂H₄O)ₙ
Molecular Weight ~ 48,000 Da
Synonyms Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1)

Frequently Asked Questions